![Rui Avelar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rui Avelar
Direttore Tecnico/Scientifico/R&S presso EVOLUS, INC.
Patrimonio netto: 5 M $ in data 31/05/2024
Profilo
Rui Avelar is currently the Chief Medical Officer, Head-Research & Development at Evolus, Inc. He previously held the position of Chief Medical Officer at Allergan Medical Optics from 2011 to 2013 and at AEON Biopharma Sub, Inc. from 2014 to 2018.
Dr. Avelar obtained his doctorate degree from the University of Toronto in 1989.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
EVOLUS, INC.
0.59% | 10/05/2024 | 368 847 ( 0.59% ) | 5 M $ | 31/05/2024 |
Posizioni attive di Rui Avelar
Società | Posizione | Inizio |
---|---|---|
EVOLUS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2014 |
Precedenti posizioni note di Rui Avelar
Società | Posizione | Fine |
---|---|---|
AEON Biopharma Sub, Inc.
![]() AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Direttore Tecnico/Scientifico/R&S | 01/02/2018 |
Allergan Medical Optics | Direttore Tecnico/Scientifico/R&S | 01/12/2013 |
Formazione di Rui Avelar
University of Toronto | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
EVOLUS, INC. | Health Technology |
Aziende private | 2 |
---|---|
AEON Biopharma Sub, Inc.
![]() AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Health Technology |
Allergan Medical Optics |
- Borsa valori
- Insiders
- Rui Avelar